India Pharma Outlook Team | Thursday, 17 July 2025
In a landmark deal that will transform diabetes care in India, Emcure Pharmaceuticals has entered an exclusive partnership with Sanofi India to sell and distribute some of Sanofi's most established oral anti-diabetic (OAD) products in the country.
Emcure will promote and sell the Sanofi partner brands Amaryl (glimepiride) and Cetapin (metformin), which are in frequent algorithmic use for type 2 diabetes.While Emcure will control all front-end activities, Sanofi will maintain ownership and production of the products in Sanofi-branded packaging at the Sanofi production facilities in India and abroad.
This arrangement is being made at a pivotal time when there are over 100 million type 2 diabetes patients in India, with approximately 60% of patients poorly controlled for blood sugar levels. It is expected that Emcure will provide more access to quality diabetes therapies, particularly in the neglected corners of the region, due to Emcure's distribution reach.
Also Read: The Future of Genomic Sequencing: Trends That Will Define the Next Decade
From an industry perspective, this partnership enables Sanofi to improve its market presence without adding any sales infrastructure while Emcure enjoys a huge advantage in the rapidly emerging chronic care sector. Additionally, no employees of either company will be transferred as part of the transaction.
Regarding the announcement, Emcure's Chief Executive Officer Satish Mehta stated the agreement aligns precisely with their goal of improving patient access to trusted therapies. Sanofi's General Manager of Southeast Asia & India Eric Mansion expressed confidence that Emcure's strong market presence will maximize the potential of their diabetes portfolio.
Overall, this partnership represents a larger trend of collaborative strategies among Indian pharma companies and focusing on improving patient access to healthcare while optimizing internal efficiencies.
